Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Southern Company (SO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Southern Company — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Southern Company trades at $90 (market cap $101.36B). The key difference: Southern Company is far larger — about 11.4× Kymera Therapeutics Inc. Common Stock's market cap, and Southern Company pays a 3.45% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Southern Company for 17 Days on average.
| KYMR | SO | |
|---|---|---|
Market Cap | $8.87B | $101.36B |
Volume | 779,107 | 6,566,089 |
Sector | Health | Utilities |
52-Week High | $127.31 | $99.72 |
52-Week Low | $55.80 | $82.35 |
Typical Hold Time | 0 Days | 17 Days |
Enterprise Value | $8.26B | $175.46B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Southern Company (SO) trades at $88.11, up 1.23% on the day, with a mixed technical outlook showing a bullish overall signal but bearish oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with Q3 2026 results pending. Revenue and net income are projected to grow in 2026, supported by a 15.43% net income margin. Analyst sentiment is cautious with a 32.35% buy rating, but the consensus price target of $96.38 suggests upside potential. Recent news highlights data center demand and dividend stability, though near-term cash flow pressure from high capital expenditures is a concern.
The outlook for SO is balanced, with long-term growth driven by utility demand and data center contracts, but near-term risks include capital expenditure pressures and potential data breach impacts. The stock offers a stable dividend and is positioned for gradual appreciation if earnings continue to outperform, yet investors should monitor cash flow trends and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Southern Company
Southern Company is a U.S. energy company with electric and gas utility businesses. Its power generation portfolio includes natural gas, nuclear, renewable, and other energy sources.
Read more on SO →
